It could mean no more having to check up on Mom or Dad every morning: Motion sensors on the wall and a monitor under the mattress one day might automatically alert you to early signs of trouble well before an elderly loved one gets sick or suffers a fall.
An instrument that quickly and more effectively analyzes complex biological and environmental samples was today named one of the past year's 100 most significant scientific and technological products or advances. The innovation was recognized by R&D Magazine in their annual R&D 100 Awards competition.
In a study reported in the July 1, 2013 Angewandte Chemie, a group of University of Illinois bioengineers have found a way to strongly adhere hydrogels to hydrophobic silicone substrates, an innovation that provides a valuable new tool for microscale biotechnology.
Inspired by studies demonstrating canine abilities to sniff out cancerous biomarkers, a team of U.K. researchers developed a scent-analysis device that they say can diagnose early signs of bladder cancer. In a test of nearly 100 urine samples, the device, called OdorReader, was 100% accurate in distinguishing which samples came from cancer patients.
Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer of the CardioChek® family of point-of-care diagnostic products, has announced the issuance of two new U.S. patents. U.S. Patent No. 8,257,654 relates to the management of health data collected by point-of-care testing devices using a health report server. U.S. Patent No. 8,307,531 covers a method and apparatus for manufacturing disposable dry test strips.
EDP Biotech, the US-based developer of a blood test to detect the early stages of colon cancer called ColoMarker™, today announced its plans to commercialize the product and bring the new technology to market. Unlike other diagnostic tests currently in development, the ColoMarker test detects a level of CA11-19 antigen.
New Data From Partners Center For Connected Health Demonstrates Wireless Mobile Technology Improves Patient Engagement, OutcomesJuly 9, 2013 10:00 am | by PR Newswire | News | Comments
A recent study conducted by the Center for Connected Health demonstrated that wireless mobile technologies can positively impact patient engagement, clinical outcomes and operational workflow in remote monitoring programs. Patients using wireless mobile devices to collect and transmit their data to the Center's secure database more frequently measured their blood pressure and uploaded their data.
Early signs of Alzheimer’s disease can be detected years before diagnosis, according to researchers at Birmingham City University. The study found that sufferers of a specific type of cognitive impairment have an increased loss of cells in certain parts of the brain, which can be vital in detecting which patients will progress to a diagnosis of Alzheimer’s.
Biotech titan Roche acquired Boston, Mass.-based medical device company Constitutional Medical Investors for a reported $220 million plus possible milestones. The Swiss company intends to beef up its diagnostics arm, Roche Diagnostics, with CMI's technology and announced plans to open a Center for Excellence in Hematology at CMI's Boston location.
A new technique for detecting cancer by imaging the consumption of sugar with magnetic resonance imaging has been unveiled by UCL scientists. The breakthrough could provide a safer and simpler alternative to standard radioactive techniques and enable radiologists to image tumors in greater detail.
Itamar-Medical Announced Today That the AMA Has Awarded a CPT Category III Code to a Test Performed by Its EndoPATTM Proprietary DeviceJuly 8, 2013 8:00 am | by Business Wire | News | Comments
Itamar-Medical Ltd (TASE: ITAMAR), developer and marketer of the EndoPAT TM non-invasive device for the assessment of endothelial function, today announced that The AMA (American Medical Association) has awarded a CPT category III reimbursement code to a test performed by its EndoPAT proprietary device.
Designers should look for a company that not only provides the right silicon, but also development tools, software, and support that are tailored for two main phases of a typical smartphone/tablet-based medical design. The first phase consists of the smartphone interface, and the second phase is the design of the medical device itself.
The exciting growth the medical telemonitoring sector has seen recently is impressive. According to Frost & Sullivan, the industry is expected to exceed double the revenues of previous years. The reason for this growth is twofold: necessity and innovation.
CEA-Leti Announces €1 Million from bpifrance to Speed Preclinical Development of Cancer-Detecting NanoparticlesJuly 3, 2013 12:15 pm | by CEA-Leti | News | Comments
CEA-Leti has announced €1 million in funding from bpifrance to accelerate preclinical development of a liver-cancer detection system called LipImage 815. The grant will accelerate the development of LipImage 815, including production and regulatory toxicity evaluation.
A new automated diagnostic test can quickly and accurately identify most leading causes of Gram-positive bacterial blood stream infections and the presence of three antibiotic resistance genes, according to a new study published this week in PLOS Medicine.
The introduction of CT pulmonary angiography has been associated with an 80% rise in the detection of pulmonary emboli in the US, but with little change in death rates. Professor Renda Soylemez Wiener and colleagues argue this is evidence of overdiagnosis.
Older adults diagnosed with brain disorders such as Parkinson’s disease often feel a loss of independence because of their lack of mobility and difficulty walking. To better understand and improve these mobility issues, a research team is working toward building a more advanced motion test.
In new research, Hao Yan and his colleagues at Arizona State University's Biodesign Institute describe a pair of tweezers shrunk down to an astonishingly tiny scale. When the jaws of these tools are in the open position, the distance between the two arms is about 16 nanometers.
Guided Therapeutics Continues to Await Update from FDA on Its PMA Application for LuViva® Advanced Cervical ScanJuly 3, 2013 8:06 am | by Business Wire | News | Comments
Guided Therapeutics commented on the status of its Pre-market Approval application for the LuViva Advanced Cervical Scan. While the Company requested a phone meeting with the FDA after the passing of their 180 day internal guidance and did speak with the agency, the company was informed that LuViva remains under FDA review.
To unlock the potential of more frequent therapy, medical devices must move out of the doctor’s office and travel with patients to their homes and offices. But, this great opportunity is not without its challenges. The same patient who stands to reap great benefit from a home medical device may instead endanger themselves by applying the device incorrectly.
Guided Therapeutics and I.T.E.M. Medical Technologies Group Announce Turkish Ministry of Health Sponsored Cervical Cancer Prevention Program Involving the LuViva® Advanced Cervical ScanJuly 2, 2013 8:29 am | by Business Wire | News | Comments
NORCROSS, Ga. & ANKARA, Turkey--(BUSINESS WIRE)--Jul 2, 2013--First graph, second sentence should read: The program for 2013 and 2014, to be funded by Turkey’s Ministry of Health (sted The program for 2013 and 2104). The corrected release reads: GUIDED THERAPEUTICS AND...
University Hospitals Case Medical Center and Case Western Reserve University Announce Licensing Agreement for the Development of Diagnostic Tests for HIV Drug ResistanceJuly 2, 2013 6:00 am | by The Associated Press | News | Comments
Case Western Reserve University has signed an exclusive worldwide licensing agreement granting University Hospitals (UH) Case Medical Center rights to a series of diagnostic tests to determine drug resistance and co-receptor tropism in human immunodeficiency virus (HIV). The phenotypic and...
As Parker sees it, the three biggest obstacles to [design] success for patient care products, such as oxygen concentrators and ventilators, are portability, battery life, and reliability. To make home care products more portable, Parker has reduced the size of some valves up to 75%.
DNA fragments in your blood may someday help doctors quickly learn if chest pain means you have narrowed heart arteries, according to a new study published in the American Heart Association journal Arteriosclerosis, Thrombosis, and Vascular Biology.
Veracyte, Inc., a molecular diagnostics company in the field of molecular cytology, today announced the completion of the final tranche of its $28 million Series C financing. The financing included GE Ventures as a new investor, as well as existing investors Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, and Versant Ventures.